ArticleAntimicrobial agents and chemotherapy2018
The Novel Fungal Cyp51 Inhibitor VT-1598 Is Efficacious in Experimental Models of Central Nervous System Coccidioidomycosis Caused by Coccidioides posadasii and Coccidioides immitis.
Article in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Trial
- The next-generation polyene EL219 is efficacious in an experimental model of central nervous system coccidioidomycosis caused byAntimicrobial agents and chemotherapy · 2026Article
- Antifungal Drugs for the Treatment of Invasive Fungal Infections-A Limited Therapeutic Toolbox Facing Growing Resistances.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Next-generation antifungal drugs: Mechanisms, efficacy, and clinical prospects.Acta pharmaceutica Sinica. B · 2025Review
- Coccidioidomycosis: a growing global concern.The Journal of antimicrobial chemotherapy · 2025Review
- Olorofim demonstratesAntimicrobial agents and chemotherapy · 2025Article
- The evolution of antifungal therapy: Traditional agents, current challenges and future perspectives.Current research in microbial sciences · 2025Review
- The Significance of Mono- and Dual-Effective Agents in the Development of New Antifungal Strategies.Chemical biology & drug design · 2025Review
- Evaluation of nikkomycin Z with frequent oral administration in an experimental model of central nervous system coccidioidomycosis.Microbiology spectrum · 2024Article
- Advancements and challenges in antifungal therapeutic development.Clinical microbiology reviews · 2024Review
- Assessment of the potential risk of oteseconazole and two other tetrazole antifungals to inhibit adrenal steroidogenesis and peripheral metabolism of corticosteroids.Frontiers in pharmacology · 2024Article
- Modeling Chronic Coccidioidomycosis in Mice.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Pharmacodynamics, Mechanisms of Action and Resistance, and Spectrum of Activity of New Antifungal Agents.Journal of fungi (Basel, Switzerland) · 2022Review
- Current Landscape of Coccidioidomycosis.Journal of fungi (Basel, Switzerland) · 2022Review
- Therapeutic Approaches for CombatingCurrent drug targets · 2022Review
- Advances in anti-fungal therapies.Mycopathologia · 2021Review
- Promising Drug Candidates and New Strategies for Fighting against the Emerging SuperbugMicroorganisms · 2021Review
- Roles for Structural Biology in the Discovery of Drugs and Agrochemicals Targeting Sterol 14α-Demethylases.Journal of fungi (Basel, Switzerland) · 2021Review
- Novel antifungal agents in clinical trials.F1000Research · 2021Review
- Investigational Agents for the Treatment of Resistant Yeasts and Molds.Current fungal infection reports · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Coccidioidal meningitis can cause significant morbidity, and lifelong antifungal therapy is often required. VT-1598 is a fungus-specific Cyp51 inhibitor that has potent
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.